COP.DE CompuGroup Medical (XETRA) €22.66 on 24 Mar 2026: Oversold bounce entry

COP.DE stock closed at €22.66 on 24 Mar 2026 on XETRA in Germany, setting up a classic oversold bounce trade as volume surged to 145,385 shares. The share price sits just above its 50-day average (€22.14) and well above the 200-day average (€19.90), giving traders a technical foothold. Short-term momentum favors buyers after a large relative volume spike (rel. vol 3.02) and a move back from the intraday low of €22.28. We examine valuation, technical triggers, risks and a trade plan framed by Meyka AI’s analysis and a conservative price forecast.

COP.DE stock: Quick market snapshot

CompuGroup Medical SE & Co. KGaA (COP.DE) closed on XETRA at €22.66, up €0.24 or 1.07% for the session. Market cap stands at €1,172,306,036.00, with 51,734,600 shares outstanding and EPS €0.52, giving a P/E of 43.58.

Today’s volume of 145,385 vs average 48,188 shows heavy participation. Key intraday levels: low €22.28, high €23.36; year range €13.10–€23.84. Exchange and currency: XETRA, Germany, EUR.

COP.DE stock: Why the oversold bounce matters

The oversold bounce signal rests on a volume-led reversal and price clustering near the 50-day average (€22.14). A rel. volume of 3.02 indicates institutional interest, which often precedes short-term recovery moves in mid-cap healthcare IT names.

Sector context matters: Healthcare peers have been weaker year-to-date, so a volume-backed bounce in COP.DE can outperform in the near term if earnings visibility improves. This setup suits tactical traders looking for a knee-jerk mean reversion with tight risk controls.

COP.DE stock: Fundamental snapshot and valuation

CompuGroup Medical reports EPS €0.52 and a trailing P/E of 43.58, while price-to-sales is 1.33 and price-to-book is 1.80. Free cash flow yield is about 9.01%, but net debt to EBITDA is 5.01, highlighting leverage sensitivity.

Margins and growth slowed in FY2024 with revenue down 2.84% and EPS down 23.86%, so the higher P/E reflects expected recovery rather than current earnings strength. Investors should weigh solid cash flow generation against elevated leverage and high intangibles.

COP.DE stock: Technical triggers and trade plan

Technical supports: €19.90 (200-day MA) and €13.10 (year low). Resistance sits near €23.84 (year high) and €24.82 (Keltner upper). ATR is €1.08, so expect daily swings around that range.

A pragmatic trade: enter a small position near €22.50–€22.80, place a stop-loss below €20.00 (just under the 200-day MA), and target €25.00 then €28.00 for partial profit taking. Risk sizing should limit downside to no more than 2.0%–3.0% of portfolio value per trade.

COP.DE stock: Meyka AI grade and forecast

Meyka AI rates COP.DE with a score out of 100: 67.80 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a base case price target €25.00 (implied upside 10.33%), a bull case €28.00 (implied upside 23.58%) and a conservative bear case €19.00 (implied downside -16.15%) versus current €22.66. Forecasts are model-based projections and not guarantees.

COP.DE stock: Catalysts, risks and outlook

Catalysts that could extend the bounce include stronger FY results, improved cash flow conversion, and positive sector data for healthcare IT. Upcoming events to watch: next confirmed earnings announcement date is 2025-11-05, and any M&A commentary could re-rate the stock.

Primary risks: high net-debt-to-EBITDA (5.01), slowing operating cash flow growth, and sensitivity to healthcare IT spending cycles. Maintain stop discipline and monitor volume for confirmation of any follow-through.

Final Thoughts

COP.DE stock offers a measurable oversold bounce opportunity after closing €22.66 on XETRA on 24 Mar 2026. The setup combines heavy intraday volume (145,385) with a price near the 50-day average (€22.14) and clear technical support at the 200-day average (€19.90). Fundamentals show mixed signals: free cash flow yield is attractive near 9.01%, but P/E of 43.58 and net-debt-to-EBITDA of 5.01 raise valuation and leverage questions. For traders, a staged entry between €22.50–€22.80 with a stop below €20.00 and targets at €25.00 and €28.00 balances reward and risk. Meyka AI’s model projects a base target of €25.00 (+10.33%) while cautioning that forecasts are model-based and not guarantees. Use position sizing and monitor volume for confirmation of sustained reversal.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.